*For patients with COPD who seek symptom relief, YUPELRI is the first and only once-daily nebulized LAMA for a full 24 hours of lung function improvement.1
YUPELRI was studied in a two 12-week, randomized, double-blind, placebo-controlled, parallel-group confirmatory studies of once-daily YUPELRI in patients with moderate to very severe COPD. The primary endpoint was change from baseline in trough (predose ) FEV1 at day 85 vs placebo: YUPELRI demonstrated a statistically significant difference vs placebo in both studies. In addition, a prespecified exploratory analysis was performed using serial spirometry on a substudy population over 24 hours on days 84 /85, which showed consistent improvement in FEV1 versus placebo over 24 hours. See results here.
icon to expand each subject area. 
Have you considered the role of nebulization in COPD maintenance therapy?
Nebulizers: a user-friendly option for COPD patients2
Many of your patients may be candidates for nebulized therapy
Consider nebulized therapy for appropriate patients.
YUPELRI delivers consistent control* over 12 weeks.
YUPELRI demonstrated consistent improvements† in trough FEV1 vs placebo over the 12-week study period.1,11
*In Study 1, LS mean change from baseline in trough FEV1 on day 85 was 127 mL (YUPELRI, n=189) and -19 mL (placebo, n=191), with a statistically significant difference vs placebo of 146 mL (P<.0001). In Study 2, LS mean change from baseline in trough FEV1 on day 85 was 102 mL (YUPELRI, n=181) and -45 mL (placebo, n=187), with a statistically significant difference of 147 mL (P<.0001).11 †The first measurement was taken at 2 weeks.
Up to 100% of patients with Medicare Part B are covered.† J-CODE J7677 Learn More
†This is not a guarantee of coverage. Site of Care will determine coverage. Check with your patient’s insurance provider for coverage rules and restrictions. In certain limited instances, YUPELRI may be covered through a patient’s Medicare Part D pharmacy benefit.
Indication
YUPELRI® inhalation solution is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
Important Safety Information
YUPELRI is contraindicated in patients with hypersensitivity to revefenacin or any component of this product.
YUPELRI should not be initiated in patients during acutely deteriorating or potentially life-threatening episodes of COPD, or for the relief of acute symptoms, i.e., as rescue therapy for the treatment of acute episodes of bronchospasm. Acute symptoms should be treated with an inhaled short-acting beta2-agonist.
